The application of anthracyclic drugs is one of the cornerstones of breast cancer treat-ment.However,the status of anthracycline drugs in the new adjuvant and adjuvant treatment of human epidermal growth factor receptor 2(HER2)positive breast cancer is facing a challenge at present,due to its cardiac toxicity and the development of new anti-HER2 drugs.This paper dis-cusses the"fate"of anthracycline drugs in new adjuvant and adjuvant treatment of HER2 positive breast cancer,bases on the recent research evidence and evidence-based medicine.
关键词
乳腺癌/HER2/蒽环/新辅助治疗/辅助治疗
Key words
breast cancer/HER2/anthracycline/neoadjuvant therapy/adjuvant therapy
维普
万方数据